Response to Comments: MolDX: Minimal Residual Disease Testing for Cancer

This document (A58953) contains responses to comments on the MolDX LCD L38814 for Minimal Residual Disease Testing for Cancer and does not itself define coverage, limitations, or frequency rules. For actionable coverage criteria, documentation requirements, and frequency limits, refer to the MolDX LCD L38814 (effective 2022-01-02).

"This document is a response to public comments on MolDX LCD L38814 (Minimal Residual Disease Testing for Cancer) and does not itself establish coverage criteria; see LCD L38814 (effective 2022-01-0..."

Sign up to see full coverage criteria, indications, and limitations.